LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the first quarter ended March 31, 2011. Cubist’s total net revenues for the first quarter of 2011 increased 13% to $162.5 million from $144.1 million in the first quarter of 2010. This increase was attributable primarily to Cubist’s net sales of CUBICIN® (daptomycin for injection) in the U.S., which increased 14% to $153.7 million in the first quarter of 2011 from $135.3 million in the first quarter of 2010. Cubist’s product revenues from international sales of CUBICIN for the first quarter of 2011 were $8.3 million, an increase of 30% over the first quarter of 2010.
